Arterial Blood Gases in Weaning of Mechanical VEntilation

Active, not recruiting

• Conditions: Weaning of Mechanical Ventilation

• Registration Number: NCT05801692
• Lead Sponsor: Centre Hospitalier Universitaire de Besancon

Brief Summary

Weaning of mechanical ventilation is an important phase of ICU (Intensive Care Unit) patient hospitalization. Patients have to pass a spontaneous breathing trial, can have a phase of pause with mechanical ventilation before extubation and then can be weaned of invasive mechanical ventilation. Spontaneous breathing trial can be performed with a T-Tube or with Pressure support without PEEP (End Expiratory Positive Pressure) . Duration of spontaneous breathing trial range from 30 minutes to 120 minutes. Some clinicians performed an arterial blood gases at the end of the spontaneous breathing trial but this practice is not really defined and clearly explained in recommendations. Patients can benefit of ventilation support after extubation like non invasive pressure support or high flow nasal canulae. The procedure can be very different from a center to another, especially for arterial blood gases at the end of spontaneous breathing trial. Our aim is to observe in a multicenter study the daily practice of weaning of mechanical ventilation especially for arterial blood gases.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-12-21
• Status Verified: 2023-01
• Study First Submitted: 2023-02-10
• Study First Submitted QC: 2023-03-24
• Last Update Submitted: 2023-03-24
• Study First Posted: 2023-04-06
• Last Update Posted: 2023-04-06
• Primary Completion: 2023-07-01
• Study Completion: 2023-10-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Older than 18 years
• first attempt of weaning of mechanical ventilation

Exclusion Criteria

• withholding of life sustaining therapies
• spontaneous breathing trial unsuccessful

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Type of spontaneous breathing trial performed	In the 24 hours of spontaneous breathing trial	Spontaneous breathing trial is performed either with pressure support or with a T-Piece

Secondary Outcome Measures

Name	Time	Method
Death	The first 28 days following extubation	If the patient died
Arterial blood gases at the end of spontaneous breathing trial	In the hour of spontaneous breathing trial	Arterial blood gases are sometime performed at the end of the spontaneous breathing trial during weaning of mechanical ventilation. Spontaneous breathing trial takes from 30 to 120 minutes
Duration of spontaneous breathing trial	The day of the spontaneous breathing trial	Duration in minutes
Need for reintubation	During the seven days following extubation	Reintubation is the need to reintubate the patient because of extubation failure
Etiology of reintubation	During the seven days following extubation	The cause of reintubation (pulmonary edema, infectious pulmonary disease...)
Ventilator associated pneumoniae	From 48 hours after extubation until extubation	Pneumoniae acquired after more than 48 hours of mechanical ventilation
Ventilatory procedure at the end of spontaneous breathing trial: either immediate extubation or pressure support ventilation with intubation	The day of extubation if extubation performed	the procedure at the end of spontaneous: the patient is either extubated immediately or benefit of about one hour of invasive pressure support with the settings before spontaneous breathing trial until extubation. Procedure of extubation is differed of about one hour.
Frequency and type of ventilatory support after extubation	The day of extubation if extubation performed	Ventilatory is either not performed or if performed, with pressure support or high flow oxygen nasal canulae
days alive without mechanical ventilation	during the first 28 days of intensive care hospitalization.	The number of days without invasive mechanical ventilation support during the first 28 days of intensive care hospitalization.

Trial Locations

Locations (1)

BARROT; 🇫🇷 Besançon, France